MDA-MB-231-Luc

Export PDF

Strain Information

Validation Data

The MDA-MB-231-Luc cell line is an MDA-MB-231 mammary carcinoma cell line with stable and high expression of Luciferase.

· The subcutaneous tumorigenesis test showed this cell line could form tumors normally in M-NSG mice.  Luciferase activity was showed a steady increase in tumor bearing mouse models.

· MDA-MB-231-Luc cells were injected into M-NSG mice via intra-femoral artery. The fluorescence signal of Luciferase increased steadily in vivo.

· In M-NSG mice, orthotopic tumors formed in mammary fat pads and it was found that metastasis could mainly occur in the liver after excision of the orthotopic tumors.

· After internal-carotid artery injection into M-NSG and Balb/C nude mice, brain metastases could form and the Luciferase fluorescence signal in brain increased significantly.

image.png

Figure 1. Morphology of MDA-MB-231-Luc cell line.

image.png

Figure 2. Luciferase activity assay of MDA-MB-231-Luc cell line.

image.png

Figure 3. (A) Average growth curves of MDA-MB-231-Luc tumors. (B) Body weights of MDA-MB-231-Luc tumor bearing mice.  (C) Survival curves of MDA-MB-231-Luc xenograft mouse models. (n=9)

MDA-MB-231-Luc cells were subcutaneously injected into M-NSG mice. 

image.png

Figure 4.  In vivo luciferase activity curves of MDA-MB-231-Luc xenograft mouse models (A: supine position, B: prone position). (n=4~5)

MDA-MB-231-Luc cells were injected into M-NSG mice via intra-femoral artery.

image.png

Figure 5.  Body weights (A) and survival curves (B) of MDA-MB-231-Luc xenograft mouse models. (n=4~5)

MDA-MB-231-Luc cells were injected into M-NSG mice via intra-femoral artery.

image.png

Figure 6. In vivo bioluminescence imaging of MDA-MB-231-Luc xenograft mouse models.

MDA-MB-231-Luc cells were injected into M-NSG mice via intra-femoral artery injection.

image.png

Figure 7. Average growth curves of MDA-MB-231-Luc orthotopic tumors in mammary fat pads. (n=5)

MDA-MB-231-Luc cells were inoculated into mammary fat pads of M-NSG mice.

image.png

Figure 8.  In vivo luciferase activity curves of MDA-MB-231-Luc orthotopic tumors in mammary fat pads. (n=5)

image.png

Figure 9. In vivo bioluminescence imaging of MDA-MB-231-Luc xenograft mouse models bearing orthotopic tumors in mammary fat pads.

image.png

Figure 10.  Survival curves of MDA-MB-231-Luc xenograft mouse models. (n=5)

image.png

Figure 11.  In vivo luciferase activity curves of MDA-MB-231-Luc xenograft mouse models after orthotopic tumors in mammary fat pads were removed. (n=3-4)

image.png

Figure 12. In vivo bioluminescence imaging of MDA-MB-231-Luc xenograft mouse models after orthotopic tumors in mammary fat pads were removed.

Luciferase activity curves showed an increase during the formation of hepatic metastases.

image.png

Figure 13. In vivo luciferase activity curves of brains in MDA-MB-231-Luc xenograft mouse models. 

MDA-MB-231-Luc cells were injected into M-NSG mice (n=3) (A) and Balb/c nude mice (n=5) (B) via internal-carotid artery.

image.png

Figure 14.  Survival curves of MDA-MB-231-Luc xenograft mouse models. 

MDA-MB-231-Luc cells were injected into M-NSG mice (n=3) (A) and Balb/C nude mice (n=5) (B) via internal-carotid artery.

image.png

Figure 15. In vivo bioluminescence imaging of brains in MDA-MB-231-Luc xenograft mouse models.  MDA-MB-231-Luc cells were injected into M-NSG mice (A) and Balb/C nude mice (B) via internal-carotid artery.



You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!

At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.

Learn more